An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial

摘要

Background: Epicutaneous immunotherapy (EPIT) for peanut allergy is a potential novel immunotherapy that utilizes the unique cutaneous immunologic properties to induce desensitization. A randomized, double-blind, placebo-controlled Phase 3 trial (PEPITES) in peanut-allergic children 4-11 years demonstrated an epicutaneous patch (DBV712) with 250 mu g peanut protein was statistically superior to placebo in inducing desensitization following 12 months of daily treatment.